Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CLS Holdings USA, Inc. (CLSH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1050-0.0277 (-20.87%)
At close: 03:52PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1327
Open0.1202
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0748 - 0.1312
52 Week Range0.0748 - 0.3896
Volume212,385
Avg. Volume76,588
Market Cap13.457M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.1160
Earnings DateOct 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CLSH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CLS HOLDINGS USA INC
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement